BioSpace News Archive

Prelude Corporation (PreludeDx), a leader in molecular diagnostics and personalized medicine for early stage breast cancer, announced today its compelling data from research on stage 1 breast cancer patients presented at the 2018 San Antonio Breast Cancer Symposium in San Antonio, TX.

Maryland University of Integrative Health (MUIH) and Leadership Maryland announced today that Steven C. “Steve” Combs, Ph.D., President and CEO of MUIH, has completed the professional development program dedicated to building a better Maryland by harnessing the strength of its local business and community leaders

Activation Clinic is making waves in the medical world of sexual wellness by joining the GAINSWave® movement to offer GAINSWave treatment!

Universal Health Services, Inc. (NYSE: UHS) announced today that that Debra K. Osteen, President of the Behavioral Health Division, will retire effective January 31, 2019.

Valneva Sweden AB, the Swedish subsidiary of Valneva SE (“Valneva”), and HOOKIPA Pharma Inc. (“HOOKIPA”) today announced that they have entered into a three-year collaboration and manufacturing agreement.

Baxter International Inc. (NYSE:BAX), a global leader in clinical nutrition, is collaborating with the European Foundation for the Care of Newborn Infants (EFCNI) to raise awareness for the new EFCNI standards that address the disparities in newborn care in Europe

SpeeDx Pty. Ltd. announced today it has received CE-IVD marking for its ResistancePlus® GC assay that detects both the sexually transmitted infection (STI) N. gonorrhoeae (GC) and sequences in the gyrA gene of the bacteria associated with susceptibility to ciprofloxacin, a previously used front-line antibiotic treatment.

Approval based on survival benefit of Tecentriq, in combination with Avastin, paclitaxel and carboplatin (chemotherapy), in people with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations compared to Avastin plus chemotherapy –

Awarded CRO 2018 Customer Value Leadership Award

Duo jointly sponsored the “Right Rebate Act of 2018,” which would give authority to the U.S. Health and Human Services Department (HHS) to fine drug companies that willfully misclassify products in Medicaid and would allow HHS to recover rebate payments